BIOMAT Database Logo BIOMAT Database Logo

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. 1996

R T Schooley, and C Ramirez-Ronda, and J M Lange, and D A Cooper, and J Lavelle, and L Lefkowitz, and M Moore, and B A Larder, and M St Clair, and J W Mulder, and R McKinnis, and K N Pennington, and P R Harrigan, and I Kinghorn, and H Steel, and J F Rooney
University of Colorado Health Science Center, Denver 80262, USA.

A randomized controlled study was done to determine whether initial combination therapy with zidovudine and zalcitabine or zidovudine and didanosine would delay the emergence of zidovudine-resistant virus. Human immunodeficiency virus (HIV)-1-infected patients with <300 CD4 cells/mm3 and <4 weeks of prior zidovudine therapy were randomized to zidovudine, zidovudine plus zalcitabine, or zidovudine plus didanosine. Combination therapy did not delay the emergence of zidovudine-resistant virus isolates. However, combination therapy resulted in a significant increase in CD4 cells through 72 weeks compared with zidovudine monotherapy and a greater and more sustained decline in serum HIV-1 RNA. Although this trial was not designed as a clinical end-point study, patients assigned to zidovudine plus didanosine combination therapy experienced a significant delay in time to first AIDS-defining event or death compared with those assigned to zidovudine monotherapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

R T Schooley, and C Ramirez-Ronda, and J M Lange, and D A Cooper, and J Lavelle, and L Lefkowitz, and M Moore, and B A Larder, and M St Clair, and J W Mulder, and R McKinnis, and K N Pennington, and P R Harrigan, and I Kinghorn, and H Steel, and J F Rooney
Studies of zidovudine in combination with didanosine and zalcitabine.
January 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
R T Schooley, and C Ramirez-Ronda, and J M Lange, and D A Cooper, and J Lavelle, and L Lefkowitz, and M Moore, and B A Larder, and M St Clair, and J W Mulder, and R McKinnis, and K N Pennington, and P R Harrigan, and I Kinghorn, and H Steel, and J F Rooney
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.
October 1993, Annals of internal medicine,
R T Schooley, and C Ramirez-Ronda, and J M Lange, and D A Cooper, and J Lavelle, and L Lefkowitz, and M Moore, and B A Larder, and M St Clair, and J W Mulder, and R McKinnis, and K N Pennington, and P R Harrigan, and I Kinghorn, and H Steel, and J F Rooney
Combination therapy with zidovudine, didanosine and saquinavir.
January 1996, Antiviral research,
R T Schooley, and C Ramirez-Ronda, and J M Lange, and D A Cooper, and J Lavelle, and L Lefkowitz, and M Moore, and B A Larder, and M St Clair, and J W Mulder, and R McKinnis, and K N Pennington, and P R Harrigan, and I Kinghorn, and H Steel, and J F Rooney
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
September 2000, AIDS research and human retroviruses,
R T Schooley, and C Ramirez-Ronda, and J M Lange, and D A Cooper, and J Lavelle, and L Lefkowitz, and M Moore, and B A Larder, and M St Clair, and J W Mulder, and R McKinnis, and K N Pennington, and P R Harrigan, and I Kinghorn, and H Steel, and J F Rooney
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
June 1999, Lancet (London, England),
R T Schooley, and C Ramirez-Ronda, and J M Lange, and D A Cooper, and J Lavelle, and L Lefkowitz, and M Moore, and B A Larder, and M St Clair, and J W Mulder, and R McKinnis, and K N Pennington, and P R Harrigan, and I Kinghorn, and H Steel, and J F Rooney
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
January 1995, Annals of internal medicine,
R T Schooley, and C Ramirez-Ronda, and J M Lange, and D A Cooper, and J Lavelle, and L Lefkowitz, and M Moore, and B A Larder, and M St Clair, and J W Mulder, and R McKinnis, and K N Pennington, and P R Harrigan, and I Kinghorn, and H Steel, and J F Rooney
Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.
November 1997, Antimicrobial agents and chemotherapy,
R T Schooley, and C Ramirez-Ronda, and J M Lange, and D A Cooper, and J Lavelle, and L Lefkowitz, and M Moore, and B A Larder, and M St Clair, and J W Mulder, and R McKinnis, and K N Pennington, and P R Harrigan, and I Kinghorn, and H Steel, and J F Rooney
In-vitro activity of zidovudine, zalcitabine, and didanosine against mycoplasmas.
November 1993, Lancet (London, England),
R T Schooley, and C Ramirez-Ronda, and J M Lange, and D A Cooper, and J Lavelle, and L Lefkowitz, and M Moore, and B A Larder, and M St Clair, and J W Mulder, and R McKinnis, and K N Pennington, and P R Harrigan, and I Kinghorn, and H Steel, and J F Rooney
High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.
July 1993, The Journal of pediatrics,
R T Schooley, and C Ramirez-Ronda, and J M Lange, and D A Cooper, and J Lavelle, and L Lefkowitz, and M Moore, and B A Larder, and M St Clair, and J W Mulder, and R McKinnis, and K N Pennington, and P R Harrigan, and I Kinghorn, and H Steel, and J F Rooney
Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
December 2000, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!